Back to Search Start Over

Metabolic changes in preclinical AD as detected by magnetic resonance spectroscopy.

Authors :
Falcon, Carles
Garcia, Marina
Julia‐Sape, Margarida
Montesinos, Paula
Sanchez‐Gonzalez, Javier
Blennow, Kaj
Zetterberg, Henrik
Kollmorgen, Gwendlyn
Carboni, Margherita
Suarez‐Calvet, Marc
Grau‐Rivera, Oriol
Gispert, Juan Domingo
Source :
Alzheimer's & Dementia: The Journal of the Alzheimer's Association; Dec2023 Supplement 14, Vol. 19, p1-4, 4p
Publication Year :
2023

Abstract

Background: Biochemical changes, which may precede morphological changes, could be of great relevance in profiling preclinical AD. We aimed to investigate metabolic changes using magnetic resonance spectroscopy (MRS) in three AD‐relevant regions: right hippocampus, right angular gyrus, and right precuneus, focusing on myoinositol due to its role in glial activity (osmoregulation‐neuroinflammation). Method: Three hundred sixty‐six participants from the ALFA+ cohort underwent three single‐voxel MRS (PRESS sequence, TR = 2000ms; TE = 100ms chosen to invert myoinositol peak for more precise quantitation; volume of interest (VOI): 20×20×20mm3 [25×20×16mm3 for hippocampus]). Figure 1 shows VOI location and MRS samples. Concentrations of N‐acetyl‐containing compounds (NAA) that is a neuronal marker, total creatine (Cr) related to brain energy, myoinositol (mI), choline‐containing compounds (Cho) related to cell proliferation, and glutamate/glutamine were calculated with LCModel in arbitrary units (using water reference) with the default settings and basis set adapted to the acquisition conditions. Concentrations were corrected for VOI CSF content. Remaining VOI gray matter percentage was used as a confounder in all analyses, jointly with age, sex, and APOE‐e4 status (carrier/non‐carrier). We investigated the correlation of MRS metabolite concentrations with CSF concentrations of Aβ42/40 and ptau‐181 as biomarkers for AD (Elecsys®; Roche Diagnostics). For completeness, we also checked the dependency of MRS metabolites on age. MRS not meeting QA criteria were discarded (Cramer‐Rao lower bounds >20 for any of the metabolites or imprecise VOI location). The statistical threshold was set to p<0.05 for all the analyses. Result: Table 1 shows characteristics of the subsamples with MRS in each location. Higher myoinositol levels in hippocampus and angular gyrus were associated with lower CSF Ab42/40, but not in the precuneus, where it was associated with higher Cr/Cho ratio. Higher Cr and NAA were positively associated with higher CSF p‐tau181 levels in the angular gyrus. NAA was negatively associated with age on cortical regions, as well as Cr on the angular gyrus. Table 2 summarizes the main results. Conclusion: MRS allowed determination of differential metabolite changes in AD‐related regions in preclinical AD. Further research is warranted to better characterize the nature of these metabolic changes and determine their impact on longitudinal outcomes of these participants. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
15525260
Volume :
19
Database :
Supplemental Index
Journal :
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Publication Type :
Academic Journal
Accession number :
174416031
Full Text :
https://doi.org/10.1002/alz.078346